MBS Day Ahead: Will Pending Home Sales Data Sing Same Tune as Other Housing Data

The National Association of Realtors publishes reports for both Pending and Existing Home Sales.  The conventional wisdom is that Pending Sales tend to foreshadow Existing Sales to some extent.  Precedent suggests that More »

MBS Day Ahead: Will Pending Home Sales Data Sing Same Tune as Other Housing Data

The National Association of Realtors publishes reports for both Pending and Existing Home Sales.  The conventional wisdom is that Pending Sales tend to foreshadow Existing Sales to some extent.  Precedent suggests that More »

Why now’s not the time for expensive tax cuts

President Trump and Republicans in Congress are on the verge of delivering a big tax cut for businesses. There’s just one catch: Neither the economy nor corporate America needs it. For years, More »

New York Mayor Bill De Blasio Begins 2nd Term at City Hall

You don’t have permission to access “http://www.usnews.com/news/best-states/new-york/articles/2018-01-01/nyc-mayor-bill-de-blasio-set-to-begin-2nd-term-at-city-hall” on this server. Reference #18.5adf02cc.1514869582.202a229a Article source: https://www.usnews.com/news/best-states/new-york/articles/2018-01-01/nyc-mayor-bill-de-blasio-set-to-begin-2nd-term-at-city-hall More »

Leader of NYC Ballet Retiring Amid Misconduct Investigation

You don’t have permission to access “http://www.usnews.com/news/best-states/new-york/articles/2018-01-01/leader-of-nyc-ballet-retiring-amid-misconduct-investigation” on this server. Reference #18.5adf02cc.1514869580.202a1bed Article source: https://www.usnews.com/news/best-states/new-york/articles/2018-01-01/leader-of-nyc-ballet-retiring-amid-misconduct-investigation More »

GeoVax Labs, Inc. (GOVX: OTCQB) | GeoVax to Present During China Showcase at Biotech Showcase 2018

Part of Larger Corporate Partnering Effort During the J.P. Morgan 36th Annual Healthcare Conference

ATLANTA, GA, Jan. 02, 2018 (GLOBE NEWSWIRE) —  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies, announced today that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will deliver a presentation at the China Showcase during the Biotech Showcase 2018 conference. Dr. Guirakhoo’s presentation will be made at 2:00 p.m. on January 7, 2018 at the Parc 55 hotel in San Francisco, California.

The China Showcase is an event for companies and investors interested in cross-border investment and strategic partnering opportunities. Dr. Guirakhoo’s presentation will focus on the broad utility and impressive dataset being developed for GeoVax’s MVA-VLP vaccine platform, and he will provide an overview of the Company’s vaccine development programs in the areas of HIV, Zika, Lassa fever, malaria, hepatitis B immunotherapy, and immuno-oncology. Following the presentation, senior management of GeoVax will be available for one-on-one meetings with investment professionals and business development representatives from the life sciences industry.

Robert McNally, PhD, GeoVax’s President CEO, commented, “While our presentation and attendance at the China Showcase is primarily focused on strategic opportunities with Chinese investors and biopharmaceutical companies, this is part of our larger effort during multiple events in San Francisco connected to the J.P. Morgan Annual Healthcare Conference on January 8-11, 2018. We continue to build a strong pipeline of preventive vaccines and immuno-therapeutics addressing multiple unmet medical needs in infectious diseases and cancer.  We look forward to connecting with many potential collaborators, partners and investors to communicate the value of our technology and the rationale for investing in the advancement of our vaccines to human clinical trials.”

Interested parties may schedule meetings with GeoVax through the conference websites for the Biotech Showcase (https://ebdgroup.knect365.com/biotech-showcase/), the Redefining Early Stage Investments (RESI) Conference (http://www.resiconference.com/), or through the partnering system hosted by the Biotechnology Innovation Organization (http://convention.bio.org/partner/). Meetings may also be scheduled by contacting Company management directly.

About GeoVax

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platforms. The Company’s HIV vaccine for the clade B epidemic in the Americas, Australia, Japan and Europe is advancing in human trials conducted by the HIV Vaccine Trials Network (HVTN). Preclinical programs are focused on preventive vaccines for Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic hepatitis B infections and cancers. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and effectively stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.

Robert T. McNally, Ph.D.
GeoVax Labs, Inc.
investor@geovax.com
678-384-7220

Primary Logo

Article source: http://www.otcmarkets.com/stock/GOVX/news?id=179327

MBS Day Ahead: Will Pending Home Sales Data Sing Same Tune as Other Housing Data

The National Association of Realtors publishes reports for both Pending and Existing Home Sales.  The conventional wisdom is that Pending Sales tend to foreshadow Existing Sales to some extent.  Precedent suggests that does indeed tend to happen more than 50% of the time.  

Case in point, Pending Sales leaped from 106.0 at the end of October to 109.3 at the end of November.  Then, true to the conventional wisdom, Existing Sales experienced a similar leap last week, moving up to a whopping 5.81 million (annual pace) from 5.48 million previously.

The interesting thing is this: as far as relative ranges are concerned, the Existing Home Sales breakout was much bigger than last month’s Pending Homes data suggested.  Based on the trendlines I drew in last week’s housing newsletter, one might even say Existing Sales are pushing the upper boundary of their trend. 

If Pending Sales manage to suggest another similar performance is in the works for January, housing metrics could really be on the verge of a shift.  Such things seem like too much to hope for given the plodding nature of the housing recovery, so we’ll count any chickens that hatch at 10am ET.

As far as bond markets are concerned, we should expect much by way of drama and certainly almost nothing by the way of “significance” at this time of year (hence all the focus on the housing-related econ data).  That doesn’t mean bonds won’t move–simply that the movement isn’t really meaningful at prevailing volumes and liquidity levels.  The day’s biggest chance for volatility surrounds the 1pm auction of 5yr Treasury Notes.

Article source: http://www.mortgagenewsdaily.com/mortgage_rates/blog/825481.aspx

MBS Day Ahead: Will Pending Home Sales Data Sing Same Tune as Other Housing Data

The National Association of Realtors publishes reports for both Pending and Existing Home Sales.  The conventional wisdom is that Pending Sales tend to foreshadow Existing Sales to some extent.  Precedent suggests that does indeed tend to happen more than 50% of the time.  

Case in point, Pending Sales leaped from 106.0 at the end of October to 109.3 at the end of November.  Then, true to the conventional wisdom, Existing Sales experienced a similar leap last week, moving up to a whopping 5.81 million (annual pace) from 5.48 million previously.

The interesting thing is this: as far as relative ranges are concerned, the Existing Home Sales breakout was much bigger than last month’s Pending Homes data suggested.  Based on the trendlines I drew in last week’s housing newsletter, one might even say Existing Sales are pushing the upper boundary of their trend. 

If Pending Sales manage to suggest another similar performance is in the works for January, housing metrics could really be on the verge of a shift.  Such things seem like too much to hope for given the plodding nature of the housing recovery, so we’ll count any chickens that hatch at 10am ET.

As far as bond markets are concerned, we should expect much by way of drama and certainly almost nothing by the way of “significance” at this time of year (hence all the focus on the housing-related econ data).  That doesn’t mean bonds won’t move–simply that the movement isn’t really meaningful at prevailing volumes and liquidity levels.  The day’s biggest chance for volatility surrounds the 1pm auction of 5yr Treasury Notes.

Article source: http://www.mortgagenewsdaily.com/mortgage_rates/blog/825481.aspx

Bunk Beds